Research Horizons


In NEJM: Dose Escalation Best Approach for Sickle Cell Med in Africa

Russell Ware, MD, PhD

“The study shows clearly that the optimized dosing strategy for hydroxyurea, though it requires more effort than a fixed-dose treatment regimen, results in far better outcomes for children with sickle cell anemia,”

— Russell Ware, MD, PhD

Read the media release about the NOHARM MTD study

Publication Information
Original title: Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa
Published in: New England Journal of Medicine
Publish date: June 25, 2020
Read the Study